Contact

Gene editing, also called genome editing, is a group of technologies to change the sequence of DNA in the genome. Several approaches to genome editing have been developed, including Zinc Finger, TALEN, and CRISPR/Cas9. Compared with the other gene editing tools, CRISPR/Cas9 system is faster, cheaper, more accurate, and more efficient, showing unprecedented advantages in gene therapy.

CRISPR/Cas9 related products

Adeno Associated Virus (AAV) CRISPR/Cas9 Servicepdf download
Adenovirus CRISPR/Cas9 Service
Lentivirus CRISPR/Cas9 Service

Content of CRISPR/Cas9-gRNA system


Introduction and principles of CRISPR gene editing system

CRISPR (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences derived from viruses that have previously infected the prokaryotes and has the ability to recognize invasive homologous DNA sequences from similar viruses, then directing Cas9 (CRISPR-associated 9) nuclease to specifically cleave them during subsequent infections, thus playing a key role in the antiviral defense system of prokaryotes [4]. Cas9 nuclease is an enzyme guided by CRISPR sequences to recognize and cleave specific nucleic acids which are complementary to the CRISPR sequence [5]. CRISPR sequences together with Cas9 enzymes make up the basis of a CRISPR/Cas9 technology which is a versatile genome-editing platform within organisms.

By 2010, three CRISPR/Cas9 systems have been identified in bacteria: type I, II and III. Derived from Streptococcus pyogenes, type II CRISPR system is relatively simple and has been eventually adapted for genome editing in mammalian cells [1]. This simpler CRISPR/Cas9 system contains four components, i.e. Cas9 endonuclease, trans-activating CRISPR RNA (tracrRNA) and two small RNA molecules named CRISPR RNA (crRNA) [2]. In this system, the mature crRNA base-paired to trans-activating crRNA (tracrRNA) forms a two-RNA structure, guiding Cas9 nuclease to mediate the recognition and cleavage of target nucleic acids [3-5]. At sites complementary to the crRNA-guide sequence, the HNH nuclease domain of Cas9 cleaves the complementary strand, whereas the RuvC-like domain of Cas9 cleaves the non-complementary strand. To target nucleic acids with more precision and expand the application of CRISPR/Cas9 system, great efforts have been paid to engineer the Cas9 enzyme or alter PAM specificities. To date, a wide range of Cas9 derivatives with novel PAM specificities have been generated using the site-depletion assay [6], and the initial two-RNA structure, ie. CRISPR RNAs (crRNAs) base-paired to trans-activating crRNA (tracrRNA), have been programmed into a "single-guide RNA (sgRNA)" (dual-tracrRNA:crRNA) by fusing the 3′ end of crRNA to the 5′ end of tracrRNA [7]. By manipulating the nucleotide sequence of the sgRNA, the artificial CRISPR/Cas9 system could be programmed to target any DNA sequence for cleavage [7].

Picture loading failed.
Figure 1. Cas9 can be programmed using a single engineered RNA molecule covering tracrRNA and crRNA features. Left, Cas9 is directed by a dual RNA structure formed by activating tracrRNA and targeting crRNA to cleave site-specifically–targeted dsDNA in type II CRISPR/Cas systems. Right, a chimeric RNA generated through fusion of crRNA to tracrRNA [7].


1) CRISPR/Cas9 gene editing system


a. Cas9: I) NHEJ mediated gene knockout; II) HDR mediated gene knockin

Guided by small guide RNA (sgRNA), Cas9 nuclease cleaves double-strand DNA, the inducing site-specific genomic double-strand breaks (DSBs). In mammalian cells, there are 2 manners with which DSBs are repaired: non-homologous end joining (NHEJ) or homology directed repair (HDR). (I) Frequently, NHEJ happens, enabling the introduction of small deletions or insertions between the ends of DSBs and resulting in frameshift mutations, and thus mediates gene knockout [8,9]. (II) With the existence of repair template, such as exogenous donor vectors, HDR takes place, introducing precise gene modifications, such as reporter insertions, and thus mediate gene knockin [10,11]. Both NHEJ mediated gene knockout HDR mediated gene knockin have been widely used in the field of gene therapy [12]. However, HDR (0.5%-20%) is much less frequent than NHEJ (20%-60%) [13], and the former only occurs during S and G2 phase while the latter can occur at any time of cell cycle [14-16]. To improve the efficiency of HDR, people have screened so many small molecules, finding that small molecules inhibitor Scr7, targeting DNA ligase IV, one key enzyme in the NHEJ pathway, significantly facilitates the HDR pathway (5%-58.3%) [17]. So far, NHEJ is widely used in the mediation of gene knockout [8,18] and correction of pathogenic gene mutation [12,19,20], while HDR is applied for knockin schemes, such as knockin cell line generation [21] or reporter/tag knockin [22].

Picture loading failed.
Figure 2. A schematic model of CRISPR system-induced non-homologous end joining (NHEJ) or homology directed repair (HDR) [23,24].

b. Cas9 nickase: off-target and D10A

Although CRISPR/Cas9 system is much cheaper, more efficient and flexible, high efficiency of off-target mutations or unwanted DNA cleavages have limited the application of this system. Mutation exploration revealed that Cas9 nickase carrying the mutation of D10A (D10A Cas9) loses the nuclease activity in RuvC domain, but does not affect the nuclease activity of HNH domain. In combination with paired gRNAs, D10A Cas9 cuts target DNA and generates two single-strand breaks with higher specificity and little off-target mutations, which is confirmed by exome sequencing analysis [25,26]. By comparing gene-disrupting efficiency of Cas9 paired nickases with that of nuclease, the T7E1 assay and deep sequencing revealed comparable on-target efficiency, even sometimes higher on-target efficiency [27]. Moreover, FACS enrichment of paired D10A Cas9 nickases will significantly facilitate efficient gene editing with minimized off-target effects [28]. Further modifications showed that hRad51–Cas9 nickase, generated by hRad51 mutants fusion with Cas9 (D10A) nickase (RDN), mediates HDR without double-stranded breaks, which results in higher HDR:indel ratios and lower off-target activity than Cas9 nuclease [29].

Picture loading failed.
Figure 3. A schematic model of paired Cas9 nickase-mediated chromosomal deletions. Newly synthesized DNA strands are shown in red [25].

c. dCas9 application: I) dCas9 activation system: MPH, VP64; II) dCas9 repression system

The nuclease-deactivated Cas9 variant, dCas9, was generated by introducing two mutations (D10A and H840A) (Figure. 2A), resulting in no catalytic activity in both RuvC domain and HNH domain [30]. With great DNA binding activity, dCas9 has been widely applied to regulate gene expression in combination with transcription activator or repressor [14,31] (Table 3). (I) dCas9 activation system: transcription activator domains (VP64, p65, MPH) or epigenetic activation modifications (p300, CBP etc.), have been fused to dCas9 to activate gene expression [32-35]; (II) dCas9 repression system: transcription repressor domains (KRAB) or epigenetic repression modifications (LSD1, DNMT3A etc.), have been fused to down-regulate the expression of target genes [34,36-38]. Besides the direct effector fusion manner, functional scaffolds (such as SunTag) can be incorporated into dCas9/sgRNA complex to recruit effectors to affect transcription [36,39]. Spatiotemporal control in dCas9/sgRNA-induced effector recruitment was also achieved upon chemical or light induction [40,41].

Picture loading failed.
Figure 4. A modular RNA-guided genome regulation platform: CRISPR/dCas9 system. Targeted by sgRNA, dCas9 can mediate transcription activation or repression via genetically fusion with specific effectors [42].

Table 1. Effectors in dCas9 systems
Effector Transcription regulation
Activator VP64 transcription activation
Activator VP48 transcription activation
Activator VP120 transcription activation
Activator p65 transcription activation
Activator MPH (MS2-P65-HSF1) transcription activation
Activator P65-HSF1 transcription activation
Activator VP64-p65-Rta transcription activation
Repressor KRAB transcription repression
Repressor SID4x transcription repression
Repressor Mxi1 transcription repression
Histone acetylation p300 transcription activation
Histone acetylation CBP transcription activation
Histone demethylation LSD1 transcription repression
DNA methylation DNMT3A transcription repression
DNA demethylation TET1 transcription activation

2) Other CRISPR system: Cas13, Cpf1, etc.


The traditional CRISPR/Cas9 system requires specific PAM sequence, which might be an obstacle to perform gene editing in some cases. Moreover, the off-target effect and cytotoxicity also limit the application of CRISPR/Cas9 system. To overcome these difficulties, researchers successfully screened several other tools to perfect the gene editing system, such as CRISPR/Cas13 and CRISPR/Cpf1. etc.

a. Cas13

Cas13 family, containing Cas13a (also known as C2c2), Cas13b and Cas13c [43], belongs to class 2 type VI and have two higher eukaryotes and prokaryotes nucleotide-binding (HEPN) endoRNase domains to mediate precise RNA cleavage in targets with protospacer flanking sites [44,45]. Cas13 enzymes are programmable and have been applied for nucleic acid detection as well as RNA knockdown and transcript tracking [46,47]. Combined with base editor, such as ADAR2 (adenosine deaminase acting on RNA type 2), catalytically inactive Cas13 (dCas13) have been used as guidance with no strict sequence constraints to direct RNA base editing, which is a promising platform with great applicability for both basic research and clinical therapy [48].

Picture loading failed. Figure 5. C2c2 (Cas13a) is a crRNA-guided RNase to cleavage of exogenous RNAs. Guided by crRNA, C2c2 mediates RNA CLEAVAGE without the need of sequence complementarity to crRNA guide sequence [44].

b. Cpf1

Distinct with Cas9 enzyme, Cpf1 is from class 2 type V CRISPR system (Prevotella and Francisella 1) and mediates DNA cleavage with three features. 1) The guiding sequence is processed into mature crRNA with no requirement of the tracrRNA. 2) Guided by mature crRNA, Cpf1 efficiently cut the DNA with a short T-rich protospacer-adjacent motif (PAM), not the G-rich PAM in Cas9 system. 3) Cpf1-crRNA system generates a staggered DNA double-stranded break with a 4 or 5-nt 5’ overhang [49]. These features greatly expand the application of CRISPR system [50].

Picture loading failed.
Figure 6. Cpf1 is a RNA-guided DNA nuclease cleaving target DNA with a T-rich protospacer-adjacent motif via a staggered DNA double-stranded break.


CRISPR/Cas9 delivery system

CRISPR/Cas9 system can be delivered in vitro by the non-viral reagents (such as polymer, liposome, nano-particle, electroporation) or viral vectors (such as lentivirus, adenovirus and AAV) and in vivo by adenovirus or AAV vectors.

1)In vitro non-viral vectors CRISPR-Cas9 delivery system

In vitro non-viral vectors CRISPR/Cas9 delivery system can be mediated by non-viral reagents, such as polymer [51], liposome [52], nano-particle [53], electroporation [54]. The characteristics of these methods are summarized in the following table 2. For more detailed information about the transfection reagents, you can refer to the website: www.genemedi.net/i/transfection-in-vitro-in-vivo.

 

Table 2 - Comparison between polymer, liposome, nano-particle.

Comparison

polymer

liposome

nano-particle

electroporation

Principle

endocytosis

endocytosis

membrane fusion/impale cells

 transient increase in the permeability of cell membrane

Integration

No

No

No

No

Time to peak expression

48h-72h

48h-72h

24h-48h

48h-72h

Sutainable time

transient expression

transient expression

transient expression

transient expression

Cell Type

a number of cell types

 adherent and suspension cell lines

Almost all the cells

not suitable for sensitive cell types

Particle diametre

75 to 520 nm

50-200nm

100-300nm

——

Animal experiment

low effiency

low effiency

target delivery

target delivery

Cytotoxicity

high

low

 non-toxic

——

Immune Response

No

No

No

No

Efficiency

low effiency (<10%)

depend on cell type

high efficiency

high efficiency

Price

 inexpensive

medium

expensive

most expensive (electroporation device)

 

2) In intro viral vectors CRISPR-Cas9 delivery system


a. lentiviral

With the ability to mediate efficient transfection and long-term expression of exogenous genes in both dividing and non-dividing cells, lentiviral is a good vector to deliver CRISPR system [55,56]. More useful information of lentivirus can be found on this website: www.genemedi.net/i/lentivirus-packaging.

b. adenoviral

Based on human adenovirus type 5 (Ad5), recombinant adenovirus (Ad) a replication-defective adenoviral vector system, is widely used for CRISPR-Cas9 system in most cell types [57-59]. Genemedi got a rich experience in adenovirus packaging, you could find more information on www.genemedi.net/i/adenovirus-packaging.

3) In vivo CRISPR-Cas9 delivery system-AAV-SaCas9


With mild immunogenicity, adeno-associated viruses (AAV) have superior biosafety rating and broad range of infectivity and mediate long-term and stable expression of CRISPR system in vivo. Considering the loading capacity of AAV (4.7kb), SaCas9 variant has been identified, referred to as KKH SaCas9, displaying robust genome editing activities at target sites with NNNRRT PAMs and showing comparable off-target effects between wild-type and KKH SaCas9 [60]. Combining CRISPR/SaCas9 system and AAV vector, AAV-SaCas9 has been widely applied for gene editing in vivo [61-63]. Genemedi is good at AAV production, please find more information on this website: www.genemedi.net/i/aav-packaging.

 

Table 3 - Comparison between Retrovirus, Lentivirus, Adenovirus and AAV vectors.

Comparison

Retrovirus

Lentivirus

Adenovirus

AAV

Genome

ss RNA

ss RNA

ds DNA

ss DNA

Integration

Yes

Yes

No

No

Packaging Capacity

3kb

4kb

5.5kb

2kb

Time to peak expression

72h

72h

36h-72h

cell: 7 days; animals: 2 weeks

Sutainable time

about 3 weeks

stable expression

transient expression

> 6 months

Cell Type

Most Dividing

Most Dividing/Non-Dividing Cells

Most Dividing/Non-Dividing Cells

Most Dividing/Non-Dividing Cells

Titeration

10^7 TU/ml

10^8 TU/ml

10^11 PFU/ml

10^12  v.g./ml

Animal experiment

suitable

low efficiency

lowest efficiency

most suitable

Immune Response

high

medium

medium

ultra-low




Protocol of CRISPR /Cas9 mediated gene knockout in vitro and in vivo


Genemedi has launched a comprehensive AAV packaging service combined with CRISPR/Cas9, the versatile genome-editing platform. The followings are some protocols of CRISPR /Cas9 mediated gene knockout in vitro and in vivo.

For AAV CRISPR/Cas9 service, please visit:

https://www.genemedi.net/i/aav-sacas9-packaging

For lentivirus CRISPR/Cas9 service, please visit:

https://www.genemedi.net/i/crispr-cas9-knockout-lentivirus-production-service

For Adenovirus CRISPR/Cas9 service, please visit:

https://www.genemedi.net/i/adenovirus-cas9-packaging

 

CRISPR/Cas9 AAV Production-User Manual

https://www.genemedi.net/pdf/Genemedi-AAV-Sa Cas9%20User%20Manual.pdf

Recombinant Adenovirus-CRISPR/Cas9 Knockout System-User Manual

https://www.genemedi.net/pdf/Genemedi-Adenovirus-crispr%20User%20Manual.pdf

Recombinant Lentivirus-CRISPR/Cas9 Knockout System-User Manual

https://www.genemedi.net/pdf/Genemedi-Lentivirus-crispr%20User%20Manual.pdf



gRNA design and validation


Cas9-gRNA design principles:

1) The PAM sequence that SpCas9 recognizes is NGG (AGG, TGG, CGG, GGG), while SaCas9 recognizes NNGRRT (NNGAAT, NNGAGT, NNGGAT, NNGGGT) or NNGRRN. For sgRNA, the length is about 21 or 22 nucleotides.

2) For sgRNA, the GC content in 40%~60% is better.

3) If the sgRNA is driven by U6 or T7 promoter, the 5’ end of sgRNA can be designed as G or GG to improve transcription efficiency, which should be considered.

4) The binding site of sgRNA should be as close to the coding region in the downstream of ATG as possible to induce frameshift mutation, the first or second exon is better.

5) SNPs should be checked in the binding site of sgRNA.

6) The distance between paired sgRNA should be taken into consideration before designing paired-gRNAs, if using Cas9 single nickase.

7) Whole genome off-target effect analysis is suggested. At least 5 bases can be allowed for the base mismatch and whether the off target is located in the gene encoding regions need to be confirmed. What’s more, base insertion or deletion in off targets should be detected.

To date, there exist so many CRISPR/Cas9 design tools, and some common tools are list in table 1.

Table 4. Common CRISPR/Cas9 design tools[64,65]

Name

Web

Affiliation

CRISPR design

http://crispr.mit.edu/

Massachusetts Institute of Technology

E-Crisp

www.e-crisp.org/E-CRISP/designcrispr

DKFZ German Cancer Research Center

CRISPR design tool

http://www.broadinstitute.org/mpg/crispr_design/

The Broad Institute of Harvard and MIT

Cas-OFFinder

http://www.rgenome.net

Harvard Medical School

CROP-IT

http://www.adlilab.org/CROP-IT/homepage.html

University of Virginia

GPP sgRNA Designer

https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design

The Broad Institute of Harvard and MIT

1)SpCas9 gRNA design, database and validation


Based on the above principles, SpCas9-gRNA can be designed on the following website [64]: https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design. Choose the CRISPR enzyme type “SpyoCas9 (NGG)”, then input transcript IDs, Gene IDs/Symbols, raw DNA sequence or upload a list of transcript IDs, Gene IDs/Symbols, a FASTA file of DNA sequences. Click on the “submit” button, and you can get and download the gRNA sequence from the following website.

Synthesize the SpCas9 gRNA sequence and its anti-sense sequence, anneal the sequences into a double chain and clone into pLv-SpCas9 vector or pAd-SpCas9 vector, which is confirmed by Sanger sequencing.

Deliver the pLv-SpCas9 vector or pAd-SpCas9 vector containing target sgRNA sequences into cells, and verify knockout efficiency.


2)SaCas9 gRNA design, database and validation



Based on the above principles, SaCas9-gRNA can be designed on the following website [64]: https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design. Choose the CRISPR enzyme type “SaurCas9 (NNGRR)”, then input transcript IDs, Gene IDs/Symbols, raw DNA sequence or upload a list of transcript IDs, Gene IDs/Symbols, a FASTA file of DNA sequences. Click on the “submit” button, and you can get and download the gRNA sequence from the following website. 

Synthesize the SaCas9 gRNA sequence and its anti-sense sequence, anneal the sequences into a double chain and clone into pAAV-SaCas9 vector, which is confirmed by Sanger sequencing.

Deliver the pAAV-SaCas9 vector containing target sgRNA sequences into cells, and verify knockout efficiency.

3)Summary of approaches for gRNA validation

The cutting efficiency of Cas9 nuclease is mainly affected gRNA target efficiency, which can be validated by T7 endonuclease I (T7EI) assay, Sanger sequencing and Western blot.

a.T7 endonuclease I (T7EI) assay
T7 Endonuclease I recognizes and cleaves non-perfectly matched DNA, which is a simple and cheap method to determine genome targeting efficiency of CRISPR/Cas9 system. First, extract the genomic DNA of cells whose genomes were targeted by Cas9. Second, perform PCR experiments to amplify target DNA. Third, anneal the PCR products and digest them with T7 Endonuclease I. Fourth, analyze the fragments with agarose gel to determine the efficiency of gRNA targeting.

Picture loading failed.

Figure 7. Principle of T7E1 assay for knockout clones

b.Sanger sequencing assay
Sanger sequencing is a direct and precise way to examine the target efficiency of gRNA. First, extract the genomic DNA of cells whose genomes were targeted by Cas9. Second, perform PCR experiments to amplify target DNA. Third, verify the sequence of target genome by Sanger sequencing and then calculate the cleavage efficiency.

c.Western blot (WB) assay
Western blot is also simple, easy but no so precise assay for the determination of gRNA targeting efficiency. First, extract the whole cell protein of cells whose genomes were targeted by Cas9. Second, perform Western blot experiments to detect the expression levels of target protein. Third, confirm the efficiency of gRNA by analyzing the WB results.

4)How to detect the off-target?

Although CRISPR/Cas9 system is a versatile gene editing technology that is widely applied in the study of basic science and translational research, high frequency of off-target activity is really a restriction factor for its therapeutic and clinical applications. So far, several methods have been used to determine the off-targets with different advantages and disadvantages [65].

 

Table 5. Common CRISPR/Cas9 design tools [65]

Method

Advantage

Disadvantage

References

T7E1 assay

Simple

Poor sensitivity, not cost-effective

[66,67]

Deep sequencing

Precise

Biased, misses potential off-target sites elsewhere in the genome

[25,68]

In silico prediction

Predicts some off-target mutation sites

Fails to predict bona-fide off-target sites

[69,70]

ChIP-seq

Unbiased detection of Cas9 binding sites genome-wide

Most off-target DNA-binding sites recognized by dCas9 are not cleaved at all by Cas9 in cells

[71-74]

GUIDE-seq

Unbiased, sensitive (0.1%), qualitative translocations, identifies breakpoint hotspots

False negatives present, limited by chromatin accessibility

[75]

HTGTS

Identifies translocations

False negatives present, limited by chromatin accessibility

[73]

IDLV

Programmable, sensitive (1%)

Many bona-fide off-target sites cannot be captured

[76]

Digenome-seq

Sensitive (0.1% or lower), unbiased and cost-effective

Not widely used

[77]

FISH

Quick

Less precise

[78]

ChIP-seq, Chromatin immunoprecipitation followed by massively parallel DNA sequencing
GUIDE-seq, Genome-wide unbiased identification of DSBs enabled by sequencing
HTGTS, high-throughput, genome-wide, translocation sequencing
IDLV, integrase-defective lentiviral vectors
FISH, fluorescence in situ hybridization

5)How to minimize off-target?

a. Alter the sgRNA sequence. Truncation of the 3′ end of sgRNA, shortening the region complementary to the target site at the 5′ end of the sgRNA by as many as 3 nt (tru-gRNA) or addition of two guanine nucleotides to the 5′ end of the sgRNA improves target specificity [79].

b. Try to optimize the design of Cas9 and sgRNA design with design tools or directed evolution [64,80].

c. Purified Cas9 ribonucleoprotein works more immediately than plasmids containing Cas9 gene sequence and can be degraded rapidly in cells, which may help minimize the off-target frequency [81,82].

d. Strategies that restrict the transcription and translation of Cas9 may help minimize off-target effects [83].

e. Replace the wild-type Cas9 nuclease with D10 mutant Cas9 nickase and paired with two sgRNAs that each cleaves only one strand [28].

f. Improve DNA cleavage specificity using fusions of dCas9 with FokI nuclease domain (fCas9) (Figure 6) [84,85]. 

Picture loading failed.

Figure 8. Architectures of Cas9 and FokI-dCas9 fusion variants. Two monomers of FokI nuclease (red) fused to dCas9-sgRNAs as shown in figure cleavage nucleic acids within the target locus. The catalytically active FokI nuclease dimer can only be assembled by adjacently bound by two FokI-dCas9 monomers to trigger dsDNA cleavage [84].


Gene editing therapy


1)Gene editing therapy vs gene replacement therapy


Gene therapy, to be brief, is delivering corrective gene materials into cells to treat or alleviate the symptom of disease [86], so far, including gene editing therapy mediated by CRISPR/Cas sytem, ZFN or TALEN etc., and gene replacement, such as lentivirus/adenovirus/AAV-mediated gene expression [20]. Gene editing therapy via CRISPR technology is to correct the pathogenic mutation into non-pathogenic ones, such as gene silence or disruption by CRISPR mediated knockout, which has been widely used in the therapy of hemophilia B [19], Huntington's disease [87], Parkinson's Disease [88], hematologic diseases, infectious diseases and malignant tumor [89]. Gene replacement therapy by lentivirus/adenovirus/AAV is to replace the pathogenic gene with its corrective type, which is widely applied in treating lipoprotein lipase deficiency (LPLD) [90], spinal muscular atrophy (SMA) [91], retinal dystrophy [92,93], cystic fibrosis [94,95] muscular dystrophies [96]. Combined CRISPR with virus vectors, AAV-SaCas9 or lentivirus-Cas9 has been used for gene therapy of Hemophilia A [61], Usher Syndrome [97], Intervertebral Disc Degeneration [98] etc.

Click here for Pipelines landscapes of gene replacement therapy and gene editing therapy of different companies..

2) Landscape of gene editing therapy: companies and pipelines 


As a powerful and versatile platform, gene editing therapy has been led into a new era. Besides basic research, great progress has been made in the clinical studied based on CRISPR. Several companies have been operated to develop transformative genomic medicines for the treatment a range of genetically addressable diseases. Founded by Zhangfeng, Jennifer A. Doudna, George Church, J. Keith Joung and David R. Liu in 2013, Editas Medicine, Inc. develops several gene medicines for disease therapy, such as EDIT-101 for the treatment of Leber Congenital Amaurosis type 10, which has entered into the phase I/II dose escalation study. Founded in Swiss in 2013, CRISPR Therapeutics has developed gene medicine CTX001 for the therapy of anemia, showing promising data in the phase I/II clinical study. Operated by Zhangfeng, David R. Liu and J. Keith Joung in 2018, Beam Therapeutics focuses on treating genetic diseases caused by point mutations with CRISPR-mediated single base editing technique. Click here for Pipelines landscapes of gene replacement therapy and gene editing therapy of different companies..



Reference

1. Sapranauskas R, G Gasiunas, C Fremaux, R Barrangou, P Horvath and V Siksnys. (2011). The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39:9275-82.
2. Barrangou R. (2015). Diversity of CRISPR-Cas immune systems and molecular machines. Genome Biol 16:247.
3. Wiedenheft B, E van Duijn, JB Bultema, SP Waghmare, K Zhou, A Barendregt, W Westphal, AJ Heck, EJ Boekema, MJ Dickman and JA Doudna. (2011). RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc Natl Acad Sci U S A 108:10092-7.
4. Bhaya D, M Davison and R Barrangou. (2011). CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45:273-97.
5. Terns MP and RM Terns. (2011). CRISPR-based adaptive immune systems. Curr Opin Microbiol 14:321-7.
6. Kleinstiver BP, MS Prew, SQ Tsai, VV Topkar, NT Nguyen, Z Zheng, AP Gonzales, Z Li, RT Peterson, JR Yeh, MJ Aryee and JK Joung. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481-5.
7. Jinek M, K Chylinski, I Fonfara, M Hauer, JA Doudna and E Charpentier. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816-21.
8. Ablain J, EM Durand, S Yang, Y Zhou and LI Zon. (2015). A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell 32:756-64.
9. Guo T, YL Feng, JJ Xiao, Q Liu, XN Sun, JF Xiang, N Kong, SC Liu, GQ Chen, Y Wang, MM Dong, Z Cai, H Lin, XJ Cai and AY Xie. (2018). Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing. Genome Biol 19:170.
10. Wang B, K Li, A Wang, M Reiser, T Saunders, RF Lockey and JW Wang. (2015). Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes. Biotechniques 59:201-2, 204, 206-8.
11. Zhang JP, XL Li, GH Li, W Chen, C Arakaki, GD Botimer, D Baylink, L Zhang, W Wen, YW Fu, J Xu, N Chun, W Yuan, T Cheng and XB Zhang. (2017). Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol 18:35.
12. Men K, X Duan, Z He, Y Yang, S Yao and Y Wei. (2017). CRISPR/Cas9-mediated correction of human genetic disease. Sci China Life Sci 60:447-457.
13. Panier S and SJ Boulton. (2014). Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 15:7-18.
14. Yang H, H Wang, CS Shivalila, AW Cheng, L Shi and R Jaenisch. (2013). One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154:1370-9.
15. Wang H, H Yang, CS Shivalila, MM Dawlaty, AW Cheng, F Zhang and R Jaenisch. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153:910-8.
16. Mali P, L Yang, KM Esvelt, J Aach, M Guell, JE DiCarlo, JE Norville and GM Church. (2013). RNA-guided human genome engineering via Cas9. Science 339:823-6.
17. Maruyama T, SK Dougan, MC Truttmann, AM Bilate, JR Ingram and HL Ploegh. (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33:538-42.
18. Roman-Rodriguez FJ, L Ugalde, L Alvarez, B Diez, MJ Ramirez, C Risueno, M Corton, M Bogliolo, S Bernal, F March, C Ayuso, H Hanenberg, J Sevilla, S Rodriguez-Perales, R Torres-Ruiz, J Surralles, JA Bueren and P Rio. (2019). NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. Cell Stem Cell 25:607-621 e7.
19. Huai C, C Jia, R Sun, P Xu, T Min, Q Wang, C Zheng, H Chen and D Lu. (2017). CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. Hum Genet 136:875-883.
20. Lamsfus-Calle A, A Daniel-Moreno, G Urena-Bailen, J Raju, JS Antony, R Handgretinger and M Mezger. (2019). Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. Blood Rev:100641.
21. Tran NT, T Sommermann, R Graf, J Trombke, J Pempe, K Petsch, R Kuhn, K Rajewsky and VT Chu. (2019). Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells. Cell Rep 28:3510-3522 e5.
22. Chen S, S Sun, D Moonen, C Lee, AY Lee, DV Schaffer and L He. (2019). CRISPR-READI: Efficient Generation of Knockin Mice by CRISPR RNP Electroporation and AAV Donor Infection. Cell Rep 27:3780-3789 e4.
23. Shalem O, NE Sanjana, E Hartenian, X Shi, DA Scott, T Mikkelson, D Heckl, BL Ebert, DE Root, JG Doench and F Zhang. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84-87.
24. San Filippo J, P Sung and H Klein. (2008). Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77:229-57.
25. Cho SW, S Kim, Y Kim, J Kweon, HS Kim, S Bae and JS Kim. (2014). Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132-41.
26. Chiang TW, C le Sage, D Larrieu, M Demir and SP Jackson. (2016). CRISPR-Cas9(D10A) nickase-based genotypic and phenotypic screening to enhance genome editing. Sci Rep 6:24356.
27. Gopalappa R, B Suresh, S Ramakrishna and HH Kim. (2018). Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption. Nucleic Acids Res 46:e71.
28. Gopalappa R, M Song, AP Chandrasekaran, S Das, S Haq, HC Koh and S Ramakrishna. (2018). Efficient genome editing by FACS enrichment of paired D10A Cas9 nickases coupled with fluorescent proteins. Arch Pharm Res 41:911-920.
29. Rees HA, WH Yeh and DR Liu. (2019). Development of hRad51-Cas9 nickase fusions that mediate HDR without double-stranded breaks. Nat Commun 10:2212.
30. Bikard D, W Jiang, P Samai, A Hochschild, F Zhang and LA Marraffini. (2013). Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 41:7429-37.
31. Cheng AW, H Wang, H Yang, L Shi, Y Katz, TW Theunissen, S Rangarajan, CS Shivalila, DB Dadon and R Jaenisch. (2013). Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23:1163-71.
32. Chavez A, J Scheiman, S Vora, BW Pruitt, M Tuttle, PRI E, S Lin, S Kiani, CD Guzman, DJ Wiegand, D Ter-Ovanesyan, JL Braff, N Davidsohn, BE Housden, N Perrimon, R Weiss, J Aach, JJ Collins and GM Church. (2015). Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12:326-8.
33. Gilbert LA, MH Larson, L Morsut, Z Liu, GA Brar, SE Torres, N Stern-Ginossar, O Brandman, EH Whitehead, JA Doudna, WA Lim, JS Weissman and LS Qi. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154:442-51.
34. Hilton IB, AM D'Ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy and CA Gersbach. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33:510-7.
35. Cheng AW, N Jillette, P Lee, D Plaskon, Y Fujiwara, W Wang, A Taghbalout and H Wang. (2016). Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling. Cell Res 26:254-7.
36. Gilbert LA, MA Horlbeck, B Adamson, JE Villalta, Y Chen, EH Whitehead, C Guimaraes, B Panning, HL Ploegh, MC Bassik, LS Qi, M Kampmann and JS Weissman. (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159:647-61.
37. Kearns NA, H Pham, B Tabak, RM Genga, NJ Silverstein, M Garber and R Maehr. (2015). Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods 12:401-403.
38. Vojta A, P Dobrinic, V Tadic, L Bockor, P Korac, B Julg, M Klasic and V Zoldos. (2016). Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res 44:5615-28.
39. Tanenbaum ME, LA Gilbert, LS Qi, JS Weissman and RD Vale. (2014). A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159:635-46.
40. Konermann S, MD Brigham, A Trevino, PD Hsu, M Heidenreich, L Cong, RJ Platt, DA Scott, GM Church and F Zhang. (2013). Optical control of mammalian endogenous transcription and epigenetic states. Nature 500:472-476.
41. Nihongaki Y, S Yamamoto, F Kawano, H Suzuki and M Sato. (2015). CRISPR-Cas9-based photoactivatable transcription system. Chem Biol 22:169-74.
42. Brocken DJW, M Tark-Dame and RT Dame. (2018). dCas9: A Versatile Tool for Epigenome Editing. Curr Issues Mol Biol 26:15-32.
43. Shmakov S, A Smargon, D Scott, D Cox, N Pyzocha, W Yan, OO Abudayyeh, JS Gootenberg, KS Makarova, YI Wolf, K Severinov, F Zhang and EV Koonin. (2017). Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 15:169-182.
44. Abudayyeh OO, JS Gootenberg, S Konermann, J Joung, IM Slaymaker, DB Cox, S Shmakov, KS Makarova, E Semenova, L Minakhin, K Severinov, A Regev, ES Lander, EV Koonin and F Zhang. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353:aaf5573.
45. East-Seletsky A, MR O'Connell, SC Knight, D Burstein, JH Cate, R Tjian and JA Doudna. (2016). Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538:270-273.
46. Gootenberg JS, OO Abudayyeh, JW Lee, P Essletzbichler, AJ Dy, J Joung, V Verdine, N Donghia, NM Daringer, CA Freije, C Myhrvold, RP Bhattacharyya, J Livny, A Regev, EV Koonin, DT Hung, PC Sabeti, JJ Collins and F Zhang. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356:438-442.
47. Abudayyeh OO, JS Gootenberg, P Essletzbichler, S Han, J Joung, JJ Belanto, V Verdine, DBT Cox, MJ Kellner, A Regev, ES Lander, DF Voytas, AY Ting and F Zhang. (2017). RNA targeting with CRISPR-Cas13. Nature 550:280-284.
48. Cox DBT, JS Gootenberg, OO Abudayyeh, B Franklin, MJ Kellner, J Joung and F Zhang. (2017). RNA editing with CRISPR-Cas13. Science 358:1019-1027.
49. Zetsche B, JS Gootenberg, OO Abudayyeh, IM Slaymaker, KS Makarova, P Essletzbichler, SE Volz, J Joung, J van der Oost, A Regev, EV Koonin and F Zhang. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163:759-71.
50. Fagerlund RD, RH Staals and PC Fineran. (2015). The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biol 16:251.
51. Kang YK, K Kwon, JS Ryu, HN Lee, C Park and HJ Chung. (2017). Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance. Bioconjug Chem 28:957-967.
52. Zhen S and X Li. (2019). Liposomal delivery of CRISPR/Cas9. Cancer Gene Ther.
53. Chin JS, WH Chooi, H Wang, W Ong, KW Leong and SY Chew. (2019). Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing. Acta Biomater 90:60-70.
54. Yamashita S, Y Kogasaka, Y Hiradate, K Tanemura and Y Sendai. (2019). Suppression of mosaic mutation by co-delivery of CRISPR associated protein 9 and three-prime repair exonuclease 2 into porcine zygotes via electroporation. J Reprod Dev.
55. Koike-Yusa H, Y Li, EP Tan, C Velasco-Herrera Mdel and K Yusa. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32:267-73.
56. McDade JR, NC Waxmonsky, LE Swanson and M Fan. (2016). Practical Considerations for Using Pooled Lentiviral CRISPR Libraries. Curr Protoc Mol Biol 115:31 5 1-31 5 13.
57. Lee J, J Ma and K Lee. (2019). Direct delivery of adenoviral CRISPR/Cas9 vector into the blastoderm for generation of targeted gene knockout in quail. Proc Natl Acad Sci U S A 116:13288-13292.
58. Romero Z, A Lomova, S Said, A Miggelbrink, CY Kuo, B Campo-Fernandez, MD Hoban, KE Masiuk, DN Clark, J Long, JM Sanchez, M Velez, E Miyahira, R Zhang, D Brown, X Wang, YZ Kurmangaliyev, RP Hollis and DB Kohn. (2019). Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. Mol Ther 27:1389-1406.
59. Lv P, X Liu, X Chen, C Liu, Y Zhang, C Chu, J Wang, X Wang, X Chen and G Liu. (2019). Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy. Nano Lett 19:2993-3001.
60. Kleinstiver BP, MS Prew, SQ Tsai, NT Nguyen, VV Topkar, Z Zheng and JK Joung. (2015). Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol 33:1293-1298.
61. Chen H, M Shi, A Gilam, Q Zheng, Y Zhang, I Afrikanova, J Li, Z Gluzman, R Jiang, LJ Kong and RY Chen-Tsai. (2019). Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep 9:16838.
62. Xu L, YS Lau, Y Gao, H Li and R Han. (2019). Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice. Mol Ther 27:1407-1414.
63. Pan X, L Philippen, SK Lahiri, C Lee, SH Park, TA Word, N Li, KE Jarrett, R Gupta, JO Reynolds, J Lin, G Bao, WR Lagor and XHT Wehrens. (2018). In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res 123:953-963.
64. Doench JG, N Fusi, M Sullender, M Hegde, EW Vaimberg, KF Donovan, I Smith, Z Tothova, C Wilen, R Orchard, HW Virgin, J Listgarten and DE Root. (2016). Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184-191.
65. Zhang XH, LY Tee, XG Wang, QS Huang and SH Yang. (2015). Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. Mol Ther Nucleic Acids 4:e264.
66. Cho SW, S Kim, JM Kim and JS Kim. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31:230-2.
67. Kim HJ, HJ Lee, H Kim, SW Cho and JS Kim. (2009). Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res 19:1279-88.
68. Cong L, FA Ran, D Cox, S Lin, R Barretto, N Habib, PD Hsu, X Wu, W Jiang, LA Marraffini and F Zhang. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339:819-23.
69. Ran FA, PD Hsu, J Wright, V Agarwala, DA Scott and F Zhang. (2013). Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281-2308.
70. Heigwer F, G Kerr and M Boutros. (2014). E-CRISP: fast CRISPR target site identification. Nat Methods 11:122-3.
71. Wu X, DA Scott, AJ Kriz, AC Chiu, PD Hsu, DB Dadon, AW Cheng, AE Trevino, S Konermann, S Chen, R Jaenisch, F Zhang and PA Sharp. (2014). Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32:670-6.
72. Duan J, G Lu, Z Xie, M Lou, J Luo, L Guo and Y Zhang. (2014). Genome-wide identification of CRISPR/Cas9 off-targets in human genome. Cell Res 24:1009-12.
73. Kuscu C, S Arslan, R Singh, J Thorpe and M Adli. (2014). Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32:677-83.
74. Singh R, C Kuscu, A Quinlan, Y Qi and M Adli. (2015). Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. Nucleic Acids Res 43:e118.
75. Tsai SQ, Z Zheng, NT Nguyen, M Liebers, VV Topkar, V Thapar, N Wyvekens, C Khayter, AJ Iafrate, LP Le, MJ Aryee and JK Joung. (2015). GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187-197.
76. Wang X, Y Wang, X Wu, J Wang, Y Wang, Z Qiu, T Chang, H Huang, RJ Lin and JK Yee. (2015). Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33:175-8.
77. Kim D, S Bae, J Park, E Kim, S Kim, HR Yu, J Hwang, JI Kim and JS Kim. (2015). Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237-43, 1 p following 243.
78. Paulis M, A Castelli, M Lizier, L Susani, F Lucchini, A Villa and P Vezzoni. (2015). A pre-screening FISH-based method to detect CRISPR/Cas9 off-targets in mouse embryonic stem cells. Sci Rep 5:12327.
79. Fu Y, JD Sander, D Reyon, VM Cascio and JK Joung. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32:279-284.
80. Lee J, MH Jung, E Jeong and JK Lee. (2019). Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution. J Vis Exp.
81. Kim S, D Kim, SW Cho, J Kim and JS Kim. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24:1012-9.
82. Ramakrishna S, AB Kwaku Dad, J Beloor, R Gopalappa, SK Lee and H Kim. (2014). Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 24:1020-7.
83. Shen CC, MN Hsu, CW Chang, MW Lin, JR Hwu, Y Tu and YC Hu. (2019). Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation. Nucleic Acids Res 47:e13.
84. Guilinger JP, DB Thompson and DR Liu. (2014). Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32:577-582.
85. Tsai SQ, N Wyvekens, C Khayter, JA Foden, V Thapar, D Reyon, MJ Goodwin, MJ Aryee and JK Joung. (2014). Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32:569-76.
86. Verma IM and N Somia. (1997). Gene therapy -- promises, problems and prospects. Nature 389:239-42.
87. Ekman FK, DS Ojala, MM Adil, PA Lopez, DV Schaffer and T Gaj. (2019). CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model. Mol Ther Nucleic Acids 17:829-839.
88. Safari F, G Hatam, AB Behbahani, V Rezaei, M Barekati-Mowahed, P Petramfar and F Khademi. (2019). CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease. Cell Mol Neurobiol.
89. Sun J, J Wang, D Zheng and X Hu. (2019). Advances in therapeutic application of CRISPR-Cas9. Brief Funct Genomics.
90. Kassner U, T Hollstein, T Grenkowitz, M Wuhle-Demuth, B Salewsky, I Demuth, M Dippel and E Steinhagen-Thiessen. (2018). Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions. Hum Gene Ther 29:520-527.
91. Passini MA, J Bu, AM Richards, CM Treleaven, JA Sullivan, CR O'Riordan, A Scaria, AP Kells, L Samaranch, W San Sebastian, T Federici, MS Fiandaca, NM Boulis, KS Bankiewicz, LS Shihabuddin and SH Cheng. (2014). Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 25:619-30.
92. Stieger K and B Lorenz. (2014). [Specific gene therapy for hereditary retinal dystrophies - an update]. Klin Monbl Augenheilkd 231:210-5.
93. Trapani I, P Colella, A Sommella, C Iodice, G Cesi, S de Simone, E Marrocco, S Rossi, M Giunti, A Palfi, GJ Farrar, R Polishchuk and A Auricchio. (2014). Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 6:194-211.
94. Doi K and Y Takeuchi. (2015). Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials. Uirusu 65:27-36.
95. Duncan GA, N Kim, Y Colon-Cortes, J Rodriguez, M Mazur, SE Birket, SM Rowe, NE West, A Livraghi-Butrico, RC Boucher, J Hanes, G Aslanidi and JS Suk. (2018). An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304.
96. Crudele JM and JS Chamberlain. (2019). AAV-based gene therapies for the muscular dystrophies. Hum Mol Genet 28:R102-R107.
97. Menghini M, J Cehajic-Kapetanovic, IH Yusuf and RE MacLaren. (2019). A novel splice-site variant in CDH23 in a patient with Usher syndrome type 1. Ophthalmic Genet:1-4.
98. Chen S, M Luo, H Kou, G Shang, Y Ji and H Liu. (2019). A Review of Gene Therapy Delivery Systems for Intervertebral Disc Degeneration. Curr Pharm Biotechnol.

Other knowledge bases

AAV Knowledge Basepdf download
CRISPR/Cas9-gRNA system Knowledge Base
Adenovirus Knowledge Basepdf download
Transfection Knowledge Base
Lentivirus Knowledge Basepdf download
Advanced cell therapy




GENEMEDI
2nd Floor, Building 21, No 518, Xinzhuan Road, Shanghai, China
Email: [email protected] [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Ask for Protocol

Apply for Protocol and guideline

×